Protagenic Therapeutics Inc. is focused on developing innovative treatments that target the regulation of stress response and the restoration of healthy brain function. Central to their approach is the utilization of Teneurin C-terminal Associated Peptides (TCAP), a naturally occurring neuropeptide that plays a crucial role in mediating stress within the brain. The company’s lead compound, PT00114, is the first synthetic analog of TCAP, which has shown promise in preclinical studies for its ability to reverse and prevent stress-induced neuropsychiatric disorders. These studies indicate that TCAP can enhance neuronal activity associated with depression, improve glucose utilization in the brain, and stabilize dendritic spines, which are vital for effective neuronal communication.

The therapeutic potential of TCAP extends beyond neuropsychiatric disorders, as Protagenic Therapeutics is also investigating its effects on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The compound has demonstrated immediate and lasting effects on brain function, with changes in gene expression that lead to durable improvements in neuronal activity. By addressing the underlying stress feedback loop that contributes to various neurobiological and psychiatric conditions, Protagenic Therapeutics aims to provide first-in-class pharmaceutical agents that meet significant unmet clinical needs in the realm of mental health and neurodegeneration.

United States

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Nervous System Diseases

Psychological Diseases

Protagenic Therapeutics Inc.

Addiction

Post-traumatic stress disorder

Social Anxiety Disorder

Treatment Resistant Depression

<p class="font_7">Corticotropin releasing hormone inhibitors</p>

PT00114

New York, New York, United States of America

Protagenic Therapeutics Inc.

Company Details